Liana Moussatos Recent News
Your Guide To 2017's Emerging Pharmaceuticals Catalysts
'Steady Growth' For Relypsa's Veltassa Launch
Every Biotech Catalyst Wedbush Is Watching In 2016
Wedbush Hikes Relypsa Target To $86 On Edge Of U.S. Veltassa Launch
Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas
EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'
Analyst: No Catalyst For Big Move In XOMA, Could Be Traders Bottom Feeding Stock
Wedbush See 470% Upside At Xoma
Relypsa Plunges After Veltassa FDA Approval; Wedbush Says 'Misunderstanding' Creates Buying Opportunity
Wedbush Thinks Pacira Pharma Is Worth $106 On Exparel Sales
Wedbush Upbeat On Vitae Pharmaceuticals Despite Diabetes Results
Wedbush Sees Bidding War For Receptos
Wedbush: Regulus Therapeutics Will Quadruple In Price Within 12 Months
Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update
Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals
Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals
Wedbush Expects Cash Runway To Last Through Anticipated Catalysts In 2015 For XOMA
XOMA Shares Spike Higher Following Wedbush Price Target Increase
Will Intercept Pharma Outperform? These Analysts Think So
Is $160 The Level To Watch At Receptos? Wedbush Thinks So
XOMA Corp Volatile Amid Differing Analyst Reports
Wedbush Securities Reacts To Regulus Therapeutics Inc Announcing ATHENA Natural History Study
Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value